UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 30, 2003
Callisto Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 333-63474 65-110840
(State or other jurisdiction (Commission (IRS Employer
of incorporation or organization) File Number) Identification No.)
420 Lexington Avenue, Suite 601
New York, New York 10170
(Address of principal executive offices)
Registrant's telephone number, including area code: (212) 672-9190
(Former name or former address, if changed since last report)
Item 5 Other Events and Required FD Disclosure
On June 30, 2003, Callisto Pharmaceuticals, Inc. announced the
appointment of new members of the Board of Directors and certain management
changes in connection with the merger agreement with Synergy Pharmaceuticals
Inc.
Item 7 - Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits
Exhibit No. Description
----------- -----------
99.1 Press Release of Callisto Pharmaceuticals, Inc. announcing
appointment of new members of the Board of Directors and
certain management changes in connection with the merger
agreement with Synergy Pharmaceuticals Inc.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, hereto duly authorized.
Dated: July 1, 2003
CALLISTO PHARMACEUTICALS, INC.
By: /s/ Gary S. Jacob
------------------------
Gary S. Jacob, Ph.D.
Chief Executive Officer
3